Skip to main content

Biontech Se ADR(BNTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low104.21
Day High112.60
Open:105.04
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
BioNTech’s Malaria mRNA Vaccine Trial Reaches Completion: What Investors Should Watch
Tipranks
Analysts Offer Insights on Healthcare Companies: Eton Pharmaceuticals (ETON), BioNTech SE (BNTX) and CareDx (CDNA)
Motley Fool
2 Healthcare Stocks to Buy and 1 to Approach With Caution
Zacks Investment Research
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings
Tipranks
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IDEAYA Biosciences (IDYA), BioNTech SE (BNTX) and Stryker (SYK)
Tipranks
Analysts Offer Insights on Healthcare Companies: Teleflex (TFX), Cigna (CI) and BioNTech SE (BNTX)
Tipranks
Analysts’ Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), BioNTech SE (BNTX)
Tipranks
BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID
Tipranks
BioNTech Calls Virtual 2026 AGM, Seeks Larger Supervisory Board to Back Oncology Push
Tipranks
Wells Fargo Issues a Buy Rating on BioNTech SE (BNTX)
Tipranks
BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
BioNTech SE (BNTX) Receives a Buy from Goldman Sachs
Tipranks
Evercore ISI Remains a Buy on BioNTech SE (BNTX)
Tipranks
Wells Fargo Sticks to Their Buy Rating for BioNTech SE (BNTX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and BioNTech SE (BNTX)
Tipranks
Deutsche Bank Keeps Their Buy Rating on BioNTech SE (BNTX)
Tipranks
BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline
Tipranks
BioNTech Co-Founders to Launch Independent mRNA Venture as Company Refocuses on Late-Stage Pipeline
Tipranks
BioNTech SE (BNTX) Receives a Buy from Morgan Stanley
Motley Fool
Stock Market Today, March 10: Oil Prices Drop on G7 Talks
Motley Fool
Why BioNTech Stock Is Getting Crushed Today
SYNDTGAM
BioNTech co-founders Ugur Sahin and Oezlem Tuereci leaving to create new company
FILE PHOTO: German Chancellor Olaf Scholz and BioNTech founders Ozlem Tureci and Ugur Sahin look at a model of plasmid at the plant of BioNTech in Marburg, Germany, February 2, 2023. REUTERS/Fabian Bimmer/File Photo
Tipranks
BioNTech Expands Oncology Pipeline With New First‑in‑Human BNT3214 Cancer Trial
Tipranks
BioNTech Expands Infectious Disease Pipeline With New Mpox mRNA Vaccine Trial in Africa
Newswire.ca
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
Tipranks
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX)
Tipranks
BioNTech’s New HIV Antibody Trial Adds Depth to BNTX’s Long-Term Pipeline Story
Tipranks
Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
Tipranks
Morgan Stanley Sticks to Their Buy Rating for BioNTech SE (BNTX)
Zacks Investment Research
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?

Profile

BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.